Agilent Technologies (A) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $1.578 billion, down 5.6% reported and 4.4% core year-over-year, but exceeded expectations and guidance, with cautious capital equipment spending offset by strong services and consumables growth.

• GAAP net income rose to $282 million ($0.97 EPS), up 155% from Q3 2023, while non-GAAP EPS was $1.32, down 8% year-over-year but above guidance.

• Operating margin improved to 27.4% (non-GAAP), with sequential gains but a year-over-year decline; company raised or reaffirmed full-year guidance for both revenue and EPS.

• Announced $925 million acquisition of BioVectra, expanding biopharma capabilities, and Sigsense, enhancing digital solutions; new segment structure implemented.

• Management noted challenging but improving market conditions, ongoing investments in growth, and a new $2 billion share repurchase program.

Financial highlights

• Q3 net revenue: $1.578 billion (down 5.6% reported, 4.4% core year-over-year); operating cash flow was $452 million; $92 million in capex; $653 million returned to shareholders via $585 million in share repurchases and $68 million in dividends.

• Q3 GAAP net income: $282 million; non-GAAP net income: $385 million; Q3 operating margin: 21.1% (GAAP), 27.4% (non-GAAP); gross margin: 56.0% (company), with segment gross margins ranging from 51.8% to 60.2%.

• Cash and cash equivalents at quarter-end: $1.78 billion; net leverage ratio ended at 0.6.

• Revenue by geography: Americas 27%, Europe 40%, Asia Pacific 33%; product mix: 35% instruments, 65% consumables/services/informatics.

• Net income for the nine months ended July 31, 2024: $938 million; cash from operations for nine months: $1.27 billion.

Outlook and guidance

• Full-year 2024 revenue expected between $6.45–$6.5 billion, a decline of 5.6%–4.9% reported and 5.0%–4.3% core; non-GAAP EPS expected between $5.21 and $5.25.

• Q4 2024 revenue guidance: $1.641–$1.691 billion, representing -1.9% to +1.1% core growth; Q4 non-GAAP EPS expected between $1.38 and $1.42.

• FY2024 operating cash flow expected at $1.5–$1.6 billion; capex at ~$400 million.

• No budget flush assumed in Q4 guidance; any such impact would benefit Q1 2025.

• Guidance excludes impact from BioVectra and Sigsense acquisitions.